NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM